{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-012549","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2024-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.356902+00:00","generated_at":"2026-05-31T00:17:17.986435+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Palatin reports FY2024 net loss $29.7M, cash $9.5M; outlines clinical milestones for obesity, DED, ED, UC","bullets":["Net loss for FY2024 $29.7M ($2.02 per share) vs $24.0M ($2.21) prior year; revenue declined as Vyleesi asset sold.","Cash and cash equivalents $9.5M at June 30, 2024; auditor includes going concern explanatory paragraph.","Obesity Phase 2 MC4R+GLP-1 trial enrollment to complete early Q4 2024; topline results expected Q1 2025.","DED Phase 3 MELODY-2/3 trials to start enrollment Q1 2025; topline results anticipated Q4 2025.","Diabetic nephropathy Phase 2 BREAKOUT topline results expected Q4 2024; UC Phase 2 interim readout Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-012549","json":"https://secwatch.observer/filing/0001654954-24-012549.json","markdown":"https://secwatch.observer/filing/0001654954-24-012549.md","text":"https://secwatch.observer/filing/0001654954-24-012549.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495424012549/0001654954-24-012549-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495424012549/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T00:17:17.986435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}